Canlyniadau Chwilio - Constance M. Barysauskas
- Dangos 1 - 4 canlyniadau o 4
-
1
Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma gan Suzanne George, Constance M. Barysauskas, César Serrano, Titilope Oduyebo, Jose Alejandro Rauh‐Hain, Marcela G. del Carmen, George D. Demetri, Michael G. Muto
Cyhoeddwyd 2014Artigo -
2
Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors gan César Serrano, Alessandro Leal, Yanan Kuang, Jeffrey A. Morgan, Constance M. Barysauskas, Jillian Phallen, Olivia Triplett, Adrián Mariño‐Enríquez, Andrew J. Wagner, George D. Demetri, Victor E. Velculescu, Cloud P. Paweletz, Jonathan A. Fletcher, Suzanne George
Cyhoeddwyd 2019Artigo -
3
Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study gan Eytan Ben‐Ami, Constance M. Barysauskas, Sarah Solomon, Kadija Tahlil, Rita Malley, Melissa Hohos, Kathleen Polson, Margaret Loucks, Mariano Severgnini, Tara Patel, Amy Cunningham, Scott J. Rodig, F. Stephen Hodi, Jeffrey A. Morgan, Priscilla Merriam, Andrew J. Wagner, Geoffrey I. Shapiro, Suzanne George
Cyhoeddwyd 2017Artigo -
4
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kin... gan Eytan Ben‐Ami, Constance M. Barysauskas, Margaret von Mehren, Michael C. Heinrich, C. L. Corless, James E. Butrynski, Jeffrey A. Morgan, Andrew J. Wagner, Edwin Choy, Jeffrey T. Yap, Annick D. Van den Abbeele, Sarah Solomon, Jonathan A. Fletcher, George D. Demetri, Stephen L. George
Cyhoeddwyd 2016Artigo
Offerynnau Chwilio:
Pynciau Perthynol
Internal medicine
Medicine
Cancer
Oncology
Biology
Clinical trial
Colorectal cancer
Confidence interval
Gastroenterology
Phases of clinical research
Regorafenib
Tyrosine-kinase inhibitor
Astrobiology
Cancer research
Chemotherapy
Clinical endpoint
Cohort
Environmental health
GiST
Hazard ratio
Hysterectomy
Imatinib
Immunotherapy
Leiomyoma
Leiomyosarcoma
Myeloid leukemia
Nivolumab
Paleontology
Pembrolizumab
Pharmacokinetics